A Phase I Trial of A-CAR032 in Participants With mCRPC

This FTiH, single-arm, open-label, investigator-initiated Phase I trial will evaluate the safety, antitumour activity, CK/pharmacodynamics (PD), biomarkers, immunogenicity, and feasibility of A-CAR032 in adult participants with mCRPC, who have previously progressed after ARPI treatment of prostate cancer (whether before or in the metastatic castration-resistant setting) and, in the judgment of the investigator, are ineligible for standard treatment.

NCT Number	NCT07344311
Lead Sponsor	Shanghai AbelZeta Ltd.
Conditions	Prostate Cancer, Metastatic Castration-Resistant Prostate Cancer
Enrollment	27 participants
Start Date	2026-01-13
Primary Completion	2027-01-31 (estimated)
Study Completion	2042-01-31 (estimated)
Updated on ClinicalTrials.gov	2026-06-01